Trials / Completed
CompletedNCT00318344
Evaluation of Atuna Racemosa Toxicity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
For thousands of years people in the South Pacific have used Atuna racemosa extract as a topical anti-inflammatory. We, the researchers at the Mayo Clinic, have shown this extract to also have antibacterial properties. While this extract has been used for decades in the South Pacific, a controlled clinical trial to evaluate toxicity has never been performed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atuna Racemosa |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2006-04-26
- Last updated
- 2010-02-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00318344. Inclusion in this directory is not an endorsement.